Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans.
The efficacy and safety of oral LY217896 for prevention of experimental influenza A/Kawasaki/86 (H1N1) virus infection were assessed in susceptible males randomly assigned to receive LY217896 (75 mg) or placebo once daily for 7 days beginning 24 h prior to viral challenge. The rates of virus shedding (100% in both groups), days of viral shedding (3.1 +/- 1.3 for the LY217896 group; 2.8 +/- 1.3 for the placebo group), and titers of virus in nasal washings did not differ between the groups. Mild upper respiratory tract illness (72% in the LY217896 group; 69% in the placebo group) developed in similar proportions of each group. LY217896 was associated with asymptomatic rises in serum uric acid levels and was ineffective in modifying the virologic or clinical course of experimental influenza A (H1N1) virus infection.
Hayden
F G
FG
University of Virginia School of Medicine, Charlottesville.
Tunkel
A R
AR
Treanor
J J
JJ
Betts
R F
RF
Allerheiligen
S
S
Harris
J
J
D000293:Adolescent; D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000998:Antiviral Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002460:Cell Line; D004285:Dogs; D004311:Double-Blind Method; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D009980:Influenza A virus; D007251:Influenza, Human / Q000382:microbiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D017817:Nasal Lavage Fluid / Q000382:microbiology; D009570:Nitriles / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D013830:Thiadiazoles / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D000914:Antibodies, Viral; D000998:Antiviral Agents; D009570:Nitriles; D013830:Thiadiazoles; C067593:1,3,4-thiadiazol-2-ylcyanamide